Palmoplantar Keratoderma Development Pipeline Analysis by DelveInsight
The Palmoplantar Keratoderma therapeutic pipeline features 3+ major pharmaceutical companies actively engaged in developing 3+ innovative treatment approaches for Palmoplantar Keratoderma management, according to DelveInsight's comprehensive analysis.
Understanding Palmoplantar Keratoderma:
Palmoplantar keratoderma (PPK) encompasses a collection of dermatological conditions marked by excessive skin thickening on the hands' palms and feet's soles. This condition may be secondary (most prevalent) resulting from medical conditions or environmental exposures, or hereditary caused by genetic alterations affecting keratin, an essential skin structural protein.
Clinical manifestations of PPK include extensive hyperkeratosis across palms and soles, frequently accompanied by erythematous borders around affected areas. Secondary keratotic formations may appear on dorsal surfaces of hands and feet, knee areas, and elbow regions. Additional characteristic features encompass hyperhidrosis and nail dystrophy.
Management approaches typically utilize topical keratolytic agents, including salicylic acid preparations and benzoic acid derivatives, designed to diminish hyperkeratotic tissue.
Access comprehensive pipeline analysis: https://www.delveinsight.com/report-store/palmoplantar-keratoderma-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=kkpr
DelveInsight's "Palmoplantar Keratoderma Pipeline Analysis 2024" delivers an extensive examination of current clinical research activities and market expansion opportunities within the Palmoplantar Keratoderma treatment sector.
Primary Findings from the PPK Pipeline Analysis
DelveInsight's comprehensive PPK pipeline assessment reveals a dynamic development environment featuring 3+ pharmaceutical companies actively pursuing 3+ therapeutic candidates for Palmoplantar Keratoderma intervention.
Leading PPK pharmaceutical companies including Sol-Gel Technologies Ltd., Krystal Biotech Inc., and additional industry players are investigating novel therapeutic agents for PPK to enhance current treatment options.
Notable PPK pipeline candidates across various developmental phases encompass SGT-210, among other promising compounds.
Latest Developments in PPK Pipeline Research:
A Phase 1b clinical investigation assessed KM-001, an innovative TRPV3 antagonist, in PPK patients, encompassing Pachyonychia Congenita (PC) and Punctate Palmoplantar Keratoderma type 1 (PPPK1). Results indicated favorable safety profiles and promising effectiveness, with 86% of Israeli participants and 88% of UK participants demonstrating enhancement in one or more outcome measures, including disease severity, pain levels, or pruritus. Significantly, 47% of all subjects improved across multiple parameters, while six of ten PC patients experienced pain amelioration.
During 2024, Sol-Gel Technologies launched a Phase 1 proof-of-concept investigation for SGT-210, focusing on PPK treatment. This research seeks to evaluate the safety profile and therapeutic potential of this innovative agent, representing a crucial advancement in PPK therapeutic development.
A Phase 2 clinical investigation is actively enrolling participants to assess Tapinarof's safety and effectiveness, a naturally derived compound previously utilized for psoriasis treatment, in adult PPK patients. This research exemplifies efforts to repurpose established dermatological therapies for PPK treatment.
In August 2024, the European Medicines Agency (EMA) awarded orphan drug status to a novel therapeutic compound, designated as (R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl)pyrrolidin-1-yl)(5-fluoropyridin-2-yl)methanone, for punctate palmoplantar keratoderma treatment. This designation supports therapeutic development for rare conditions such as PPK.
PPK Pipeline Comprehensive Review
The analysis encompasses:
- Detailed examination of leading pharmaceutical companies developing PPK therapeutics
- Assessment of therapeutic candidates categorized by developmental phases: early-stage, mid-stage, and late-stage PPK treatments
- Analysis of key industry players involved in targeted therapeutic development, including active and dormant projects
- Investigation of emerging therapeutics based on developmental stage, administration route, target mechanisms, monotherapy versus combination approaches, mechanistic diversity, and molecular classifications
- Comprehensive evaluation of partnerships (industry collaborations and academic partnerships), licensing arrangements, and funding details for future PPK market advancement
Download complimentary sample: https://www.delveinsight.com/sample-request/palmoplantar-keratoderma-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=kkpr
Emerging PPK Therapeutics
SGT-210: Sol-Gel Technologies Ltd.
PPK Industry Players
Approximately three or more pharmaceutical companies are currently developing PPK therapies. Sol-Gel Technologies Ltd. maintains the most advanced therapeutic candidate, currently undergoing Phase I clinical evaluation.
DelveInsight's analysis encompasses 3+ therapeutic products across multiple clinical developmental stages:
- Advanced-stage candidates (Phase III)
- Mid-stage candidates (Phase II)
- Early-stage candidates (Phase I) including:
- Pre-clinical and Discovery phase compounds
- Discontinued & Inactive therapeutic candidates
PPK Pipeline Assessment by Administration Route
Therapeutic products are classified under various administration methods:
- Intravenous delivery
- Subcutaneous injection
- Oral administration
- Intramuscular injection
PPK Products by Molecular Classification
Therapeutic candidates are categorized by molecular structure:
- Monoclonal antibody therapeutics
- Small molecule compounds
- Peptide-based therapies
Access detailed assessment: https://www.delveinsight.com/report-store/palmoplantar-keratoderma-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=kkpr
PPK Pipeline Treatment Evaluation
- PPK Assessment by Therapeutic Category
- PPK By Developmental Phase
- PPK Assessment by Administration Method
- PPK Assessment by Molecular Structure
Download comprehensive market analysis: https://www.delveinsight.com/sample-request/palmoplantar-keratoderma-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=kkpr
Report Structure
- Introduction and Scope
- Executive Overview
- Current PPK Treatment Approaches
- PPK - DelveInsight's Strategic Analysis
- Treatment Assessment
- PPK Advanced-Stage Therapeutics (Phase-III)
- PPK Mid-Stage Therapeutics (Phase-II)
- Early-Stage Therapeutics (Phase-I)
- Pre-clinical and Discovery Stage Therapeutics
- Inactive Therapeutic Candidates
- Dormant Therapeutic Candidates
- PPK Discontinued Therapeutics
- PPK Therapeutic Profiles
- PPK Leading Companies
- PPK Key Therapeutics
- Dormant and Discontinued Therapeutics
- PPK Unmet Clinical Needs
- PPK Future Market Outlook
- PPK Expert Analysis
- Supplementary Information
- Research Methodology
Request comprehensive sample report: https://www.delveinsight.com/report-store/palmoplantar-keratoderma-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=kkpr
About DelveInsight
DelveInsight operates as a premier Business Consulting and Market Research organization specializing exclusively in life sciences sectors. The company provides pharmaceutical organizations with comprehensive, end-to-end solutions designed to enhance operational performance.
Contact Information:
Kanishk
Email: kkumar@delveinsight.com
General: info@delveinsight.com
Phone: +14699457679
English
Dutch